Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 56 entries
Sorted by: Best Match Show Resources per page
What's hot in the prostate?.

Prostate cancer and prostatic diseases

Belldegrun A.
PMID: 12496857
Prostate Cancer Prostatic Dis. 1999 Jan;2(1):1-2. doi: 10.1038/sj.pcan.4500284.

No abstract available.

Cite
Belldegrun A. What's hot in the prostate?. Prostate Cancer Prostatic Dis. 1999;2(1):1-2doi: 10.1038/sj.pcan.4500284.
Belldegrun, A. (1999). What's hot in the prostate?. Prostate cancer and prostatic diseases, 2(1), 1-2. https://doi.org/10.1038/sj.pcan.4500284
Belldegrun, Arie. "What's hot in the prostate?." Prostate cancer and prostatic diseases vol. 2,1 (1999): 1-2. doi: https://doi.org/10.1038/sj.pcan.4500284
Belldegrun A. What's hot in the prostate?. Prostate Cancer Prostatic Dis. 1999 Jan;2(1):1-2. doi: 10.1038/sj.pcan.4500284. PMID: 12496857.
Copy Download .nbib Format: NLM
Gene therapy for prostate cancer.

Prostate cancer and prostatic diseases

Naitoh J, Belldegrun A.
PMID: 12496894
Prostate Cancer Prostatic Dis. 1998 Jun;1(4):189-196. doi: 10.1038/sj.pcan.4500242.

The treatment options for the patient with advanced prostate cancer are limited. Due to the recent advances in the understanding of the molecular biology of prostate cancer, the easy accessibility of the gland for injection, and the availability of...

Cite
Naitoh J, Belldegrun A. Gene therapy for prostate cancer. Prostate Cancer Prostatic Dis. 1998;1(4):189-196doi: 10.1038/sj.pcan.4500242.
Naitoh, J., & Belldegrun, A. (1998). Gene therapy for prostate cancer. Prostate cancer and prostatic diseases, 1(4), 189-196. https://doi.org/10.1038/sj.pcan.4500242
Naitoh, J, and Belldegrun, A. "Gene therapy for prostate cancer." Prostate cancer and prostatic diseases vol. 1,4 (1998): 189-196. doi: https://doi.org/10.1038/sj.pcan.4500242
Naitoh J, Belldegrun A. Gene therapy for prostate cancer. Prostate Cancer Prostatic Dis. 1998 Jun;1(4):189-196. doi: 10.1038/sj.pcan.4500242. PMID: 12496894.
Copy Download .nbib Format: NLM
What's hot in the prostate?.

Prostate cancer and prostatic diseases

Belldegrun A.
PMID: 12497055
Prostate Cancer Prostatic Dis. 2001;4(1):1-4. doi: 10.1038/sj.pcan.4500513.

No abstract available.

Cite
Belldegrun A. What's hot in the prostate?. Prostate Cancer Prostatic Dis. 2001;4(1):1-4doi: 10.1038/sj.pcan.4500513.
Belldegrun, A. (2001). What's hot in the prostate?. Prostate cancer and prostatic diseases, 4(1), 1-4. https://doi.org/10.1038/sj.pcan.4500513
Belldegrun, Arie. "What's hot in the prostate?." Prostate cancer and prostatic diseases vol. 4,1 (2001): 1-4. doi: https://doi.org/10.1038/sj.pcan.4500513
Belldegrun A. What's hot in the prostate?. Prostate Cancer Prostatic Dis. 2001;4(1):1-4. doi: 10.1038/sj.pcan.4500513. PMID: 12497055.
Copy Download .nbib Format: NLM
Urology in the desert 2000: highlights from the 76th annual meeting of the Western section american urological association.

Reviews in urology

Zisman A, Pantuck AJ, Freedland SJ, Belldegrun AS.
PMID: 16985697
Rev Urol. 2001;3(2):99-101.

No abstract available.

Cite
Zisman A, Pantuck AJ, Freedland SJ, et al. Urology in the desert 2000: highlights from the 76th annual meeting of the Western section american urological association. Rev Urol. 2001;3(2):99-101
Zisman, A., Pantuck, A. J., Freedland, S. J., & Belldegrun, A. S. (2001). Urology in the desert 2000: highlights from the 76th annual meeting of the Western section american urological association. Reviews in urology, 3(2), 99-101.
Zisman, A, et al. "Urology in the desert 2000: highlights from the 76th annual meeting of the Western section american urological association." Reviews in urology vol. 3,2 (2001): 99-101.
Zisman A, Pantuck AJ, Freedland SJ, Belldegrun AS. Urology in the desert 2000: highlights from the 76th annual meeting of the Western section american urological association. Rev Urol. 2001;3(2):99-101. PMID: 16985697; PMCID: PMC1476044.
Copy Download .nbib Format: NLM
Nephron-sparing surgery for renal cell carcinoma.

Reviews in urology

Tsui KH, van Ophoven A, Shvarts O, Belldegrun A.
PMID: 16985800
Rev Urol. 1999;1(4):216-25.

Nephron-sparing surgery has become an established surgical treatment for patients with renal cell carcinoma (RCC), particularly in situations in which preservation of renal parenchyma is critical. However, due to the fear of local renal fossa recurrence with nephron-sparing surgery,...

Cite
Tsui KH, van Ophoven A, Shvarts O, et al. Nephron-sparing surgery for renal cell carcinoma. Rev Urol. 1999;1(4):216-25
Tsui, K. H., van Ophoven, A., Shvarts, O., & Belldegrun, A. (1999). Nephron-sparing surgery for renal cell carcinoma. Reviews in urology, 1(4), 216-25.
Tsui, K H, et al. "Nephron-sparing surgery for renal cell carcinoma." Reviews in urology vol. 1,4 (1999): 216-25.
Tsui KH, van Ophoven A, Shvarts O, Belldegrun A. Nephron-sparing surgery for renal cell carcinoma. Rev Urol. 1999;1(4):216-25. PMID: 16985800; PMCID: PMC1477533.
Copy Download .nbib Format: NLM
Laparoscopic and percutaneous ablative techniques in the treatment of renal cell carcinoma.

Reviews in urology

Perry K, Zisman A, Pantuck AJ, Janzen N, Schulam P, Belldegrun AS.
PMID: 16985666
Rev Urol. 2002;4(3):103-11.

Widespread use of computed tomography, ultrasound, and magnetic resonance imaging has led to an increase in detection of relatively small renal masses, and approaches to managing them have evolved in the last two decades. Indications for nephron-sparing surgery have...

Cite
Perry K, Zisman A, Pantuck AJ, et al. Laparoscopic and percutaneous ablative techniques in the treatment of renal cell carcinoma. Rev Urol. 2002;4(3):103-11
Perry, K., Zisman, A., Pantuck, A. J., Janzen, N., Schulam, P., & Belldegrun, A. S. (2002). Laparoscopic and percutaneous ablative techniques in the treatment of renal cell carcinoma. Reviews in urology, 4(3), 103-11.
Perry, Kent, et al. "Laparoscopic and percutaneous ablative techniques in the treatment of renal cell carcinoma." Reviews in urology vol. 4,3 (2002): 103-11.
Perry K, Zisman A, Pantuck AJ, Janzen N, Schulam P, Belldegrun AS. Laparoscopic and percutaneous ablative techniques in the treatment of renal cell carcinoma. Rev Urol. 2002;4(3):103-11. PMID: 16985666; PMCID: PMC1475990.
Copy Download .nbib Format: NLM
Therapeutic strategies, predicting outcomes in patients with renal cell and transitional cell carcinomas.

Reviews in urology

Pantuck A, Zisman A, Belldegrun A.
PMID: 16985727
Rev Urol. 2000;2(1):22-4.

No abstract available.

Cite
Pantuck A, Zisman A, Belldegrun A. Therapeutic strategies, predicting outcomes in patients with renal cell and transitional cell carcinomas. Rev Urol. 2000;2(1):22-4
Pantuck, A., Zisman, A., & Belldegrun, A. (2000). Therapeutic strategies, predicting outcomes in patients with renal cell and transitional cell carcinomas. Reviews in urology, 2(1), 22-4.
Pantuck, A, et al. "Therapeutic strategies, predicting outcomes in patients with renal cell and transitional cell carcinomas." Reviews in urology vol. 2,1 (2000): 22-4.
Pantuck A, Zisman A, Belldegrun A. Therapeutic strategies, predicting outcomes in patients with renal cell and transitional cell carcinomas. Rev Urol. 2000;2(1):22-4. PMID: 16985727; PMCID: PMC1476093.
Copy Download .nbib Format: NLM
Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.

European urology

Shuch B, Belldegrun A.
PMID: 18485320
Eur Urol. 2008 May;53(5):1085-6. doi: 10.1016/j.eururo.2008.02.010.

No abstract available.

Cite
Shuch B, Belldegrun A. Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. Eur Urol. 2008;53(5):1085-6doi: 10.1016/j.eururo.2008.02.010.
Shuch, B., & Belldegrun, A. (2008). Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. European urology, 53(5), 1085-6. https://doi.org/10.1016/j.eururo.2008.02.010
Shuch, Brian, and Belldegrun, Arie. "Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma." European urology vol. 53,5 (2008): 1085-6. doi: https://doi.org/10.1016/j.eururo.2008.02.010
Shuch B, Belldegrun A. Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. Eur Urol. 2008 May;53(5):1085-6. doi: 10.1016/j.eururo.2008.02.010. PMID: 18485320.
Copy Download .nbib Format: NLM
Systemic therapy for metastatic renal cell carcinoma: a review and update.

Reviews in urology

Logan JE, Rampersaud EN, Sonn GA, Chamie K, Belldegrun AS, Pantuck AJ, Slamon DJ, Kabbinavar FF.
PMID: 23526579
Rev Urol. 2012;14(3):65-78.

An in-depth understanding of metastatic renal cell carcinoma (mRCC) is important so that practitioners can make informed evidenced-based decisions with patients to optimize not only quantity of life but quality of life as well. Therefore, this review focuses on...

Cite
Logan JE, Rampersaud EN, Sonn GA, et al. Systemic therapy for metastatic renal cell carcinoma: a review and update. Rev Urol. 2012;14(3):65-78
Logan, J. E., Rampersaud, E. N., Sonn, G. A., Chamie, K., Belldegrun, A. S., Pantuck, A. J., Slamon, D. J., & Kabbinavar, F. F. (2012). Systemic therapy for metastatic renal cell carcinoma: a review and update. Reviews in urology, 14(3), 65-78.
Logan, Joshua E, et al. "Systemic therapy for metastatic renal cell carcinoma: a review and update." Reviews in urology vol. 14,3 (2012): 65-78.
Logan JE, Rampersaud EN, Sonn GA, Chamie K, Belldegrun AS, Pantuck AJ, Slamon DJ, Kabbinavar FF. Systemic therapy for metastatic renal cell carcinoma: a review and update. Rev Urol. 2012;14(3):65-78. PMID: 23526579; PMCID: PMC3602729.
Copy Download .nbib Format: NLM
What's hot in the prostate?.

Prostate cancer and prostatic diseases

Belldegrun A.
PMID: 12496901
Prostate Cancer Prostatic Dis. 1998 Mar;1(3):105-107. doi: 10.1038/sj.pcan.4500231.

No abstract available.

Cite
Belldegrun A. What's hot in the prostate?. Prostate Cancer Prostatic Dis. 1998;1(3):105-107doi: 10.1038/sj.pcan.4500231.
Belldegrun, A. (1998). What's hot in the prostate?. Prostate cancer and prostatic diseases, 1(3), 105-107. https://doi.org/10.1038/sj.pcan.4500231
Belldegrun, A. "What's hot in the prostate?." Prostate cancer and prostatic diseases vol. 1,3 (1998): 105-107. doi: https://doi.org/10.1038/sj.pcan.4500231
Belldegrun A. What's hot in the prostate?. Prostate Cancer Prostatic Dis. 1998 Mar;1(3):105-107. doi: 10.1038/sj.pcan.4500231. PMID: 12496901.
Copy Download .nbib Format: NLM
What's hot in the prostate?.

Prostate cancer and prostatic diseases

Belldegrun Eb.
PMID: 12497040
Prostate Cancer Prostatic Dis. 2001;4(2):67-70. doi: 10.1038/sj.pcan.4500524.

No abstract available.

Cite
Belldegrun Eb. What's hot in the prostate?. Prostate Cancer Prostatic Dis. 2001;4(2):67-70doi: 10.1038/sj.pcan.4500524.
Belldegrun Eb. (2001). What's hot in the prostate?. Prostate cancer and prostatic diseases, 4(2), 67-70. https://doi.org/10.1038/sj.pcan.4500524
Belldegrun Eb, Edited by Arie. "What's hot in the prostate?." Prostate cancer and prostatic diseases vol. 4,2 (2001): 67-70. doi: https://doi.org/10.1038/sj.pcan.4500524
Belldegrun Eb. What's hot in the prostate?. Prostate Cancer Prostatic Dis. 2001;4(2):67-70. doi: 10.1038/sj.pcan.4500524. PMID: 12497040.
Copy Download .nbib Format: NLM
Intermittent androgen deprivation therapy: schedule modifications based on a novel in vivo human xenograft model.

Prostate cancer and prostatic diseases

Pantuck AJ, Zismon A, Tso CL, Belldegrun AS.
PMID: 12497078
Prostate Cancer Prostatic Dis. 2000 Dec;3(4):280-282. doi: 10.1038/sj.pcan.4500473.

In most clinical trials of intermittent androgen deprivation (IAD), the decision to stop androgen withdrawal is based on monitoring PSA levels, waiting for its drop to nadir. Based on in vitro pre-clinical studies, a modified 'on-off' schedule of short...

Cite
Pantuck AJ, Zismon A, Tso CL, et al. Intermittent androgen deprivation therapy: schedule modifications based on a novel in vivo human xenograft model. Prostate Cancer Prostatic Dis. 2000;3(4):280-282doi: 10.1038/sj.pcan.4500473.
Pantuck, A. J., Zismon, A., Tso, C. L., & Belldegrun, A. S. (2000). Intermittent androgen deprivation therapy: schedule modifications based on a novel in vivo human xenograft model. Prostate cancer and prostatic diseases, 3(4), 280-282. https://doi.org/10.1038/sj.pcan.4500473
Pantuck, A J, et al. "Intermittent androgen deprivation therapy: schedule modifications based on a novel in vivo human xenograft model." Prostate cancer and prostatic diseases vol. 3,4 (2000): 280-282. doi: https://doi.org/10.1038/sj.pcan.4500473
Pantuck AJ, Zismon A, Tso CL, Belldegrun AS. Intermittent androgen deprivation therapy: schedule modifications based on a novel in vivo human xenograft model. Prostate Cancer Prostatic Dis. 2000 Dec;3(4):280-282. doi: 10.1038/sj.pcan.4500473. PMID: 12497078.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 56 entries